Compare H World Group Limited American Depositary Shares (HTHT) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H World Group Limited American Depositary Shares vs Organon & Co. Common Stock — how do they compare? H World Group Limited American Depositary Shares trades at $44.2 (market cap $14.00B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: H World Group Limited American Depositary Shares is far larger — about 3.9× Organon & Co. Common Stock's market cap, and H World Group Limited American Depositary Shares pays the higher dividend (4.91%). Which is the better fit depends on your goals — on Pluang, investors hold H World Group Limited American Depositary Shares for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| HTHT | OGN | |
|---|---|---|
Market Cap | $14.00B | $3.61B |
Volume | 1,318,511 | 1,808,049 |
Sector | Consumer Cyclical | Health |
52-Week High | $56.06 | $13.81 |
52-Week Low | $36.99 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $16.79B | $11.03B |
Dividend Yield | 4.91% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTHT trades at $44.17, down 0.85% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.78 exceeding the $0.74 estimate. Revenue for 2025 was $25.31 billion, with a net income margin of 18.93% and robust ROE of 38.39%. Positive news highlights the asset-light model's margin improvement and a recent CNY bond offering.
The outlook remains positive with a consensus price target of $50.56, implying 14.5% upside, supported by earnings momentum and operational efficiency. Key risks include market saturation in China and reliance on domestic growth. Analyst sentiment is bullish with 11 buy ratings out of 19, though valuation multiples like a P/E of 31.46 warrant monitoring.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About H World Group Limited American Depositary Shares
H World Group operates hotels through leased and owned, managed franchise, and franchise models. Its brands include HanTing, JI Hotel, Orange Hotel, and Steigenberger Hotels & Resorts.
Read more on HTHT →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
